COMPOSITIONS AND METHODS RELATED TO RAD51 INACTIVATION IN THE TREATMENT OF NEOPLASTIC DISEASES, AND ESPECIALLY CML

Chronic myelogenous leukemia (CML), and in particular imatinib resistant CML is treated using compositions and methods in which a Rad51-inhibitor and a kinase inhibitor are administered. Most preferably, the Rad51 inhibitor comprises an indolyl isoquinoline structure and the kinase inhibitor is a BC...

Full description

Saved in:
Bibliographic Details
Main Authors ZHOU, LONGEN, CHEN, PHANG-LANG, LEE, WEN-HWA, ZHU, JIEWEN
Format Patent
LanguageEnglish
French
Published 25.10.2007
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Chronic myelogenous leukemia (CML), and in particular imatinib resistant CML is treated using compositions and methods in which a Rad51-inhibitor and a kinase inhibitor are administered. Most preferably, the Rad51 inhibitor comprises an indolyl isoquinoline structure and the kinase inhibitor is a BCR-ABL inhibitor. La présente invention concerne la leucémie myéloïde chronique (LMC) et, plus particulièrement, la LMC résistant à l'imatinibe qui est traitée à l'aide de compositions et de procédés au cours desquels on administre un inhibiteur du Rad51 et un inhibiteur de la kinase. Idéalement, l'inhibiteur du Rad51 comprend une structure indolyle isoquinoline et l'inhibiteur de la kinase est un inhibiteur BCR-ABL.
Bibliography:Application Number: WO2007US08969